GO
Loading...

AstraZeneca PLC

More

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. drugmaker AbbVie has pulled the plug on its plan to buy Dublin- based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. pharmaceutical company AbbVie has pulled the plug on its plan to buy Dublin- based drugmaker Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • *AbbVie says reconsidering backing for deal. *AbbVie board to meet on Oct. 20. LONDON, Oct 15- Chicago- based AbbVie said it was reconsidering its $55 billion takeover of Shire weeks after the U.S. government moved to curb deals designed to reduce tax, wiping $13 billion off the London- listed firm's stock price.

  • LONDON, Oct 15- European shares fell on Wednesday, weighed down by UK healthcare stocks after U.S. suitor AbbVie Inc said it would reconsider its bid for UK pharmaceutical firm Shire. Shares in Shire fell nearly 30 percent in early deals after AbbVie said it intended to reconsider its recommendation to shareholders to vote in favor of the 32 billion pound merger...

  • Oct 14- AbbVie Inc said it intends to reconsider its recommendation to its shareholders to vote in favor of the 32 billion pound merger with Shire Plc due to the changing U.S. tax regulations. Chicago- based AbbVie, which makes top-selling arthritis drug Humira, is eager to buy Shire to reduce its U.S. tax bill by moving its tax base to Britain and to diversifying its...

  • New health care acquisition worth $12.2B Monday, 6 Oct 2014 | 8:53 AM ET

    The announcement is the latest in a recent spate of multibillion-dollar healthcare sector deals.

  • LONDON, Oct 6- AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. AstraZeneca said on Monday it was the first time the cardiology organizations had recommended one drug of this type over another in the treatment of acute...

  • Oct 5- Medical equipment supplier Becton Dickinson& Co has agreed to buy CareFusion Corp, a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal. Becton said on Sunday it would pay a total of $58.00 a share- $49.00 in cash and 0.0777 of a share of Becton Dickinson- for...

  • Goldman tops M&A league, tax inversion deals soar Thursday, 2 Oct 2014 | 2:57 AM ET

    Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions.

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • Oct 1- Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.

  • Update 1-Ardelyx bowel drug succeeds in mid-stage trial Wednesday, 1 Oct 2014 | 8:55 AM ET

    Oct 1- Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.

  • Oct 1- Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared to a placebo in a mid-stage study involving 371 patients. Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc in October 2012.

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • Sept 30- Johnson& Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. It will compete with Nektar Therapeutics and AstraZeneca Plc's oral drug Movantik, approved by the FDA earlier this month for the same patient population.

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. Salix, which is merging with Cosmo Pharmaceuticals SpA's Irish subsidiary, is in talks with Allergan Inc and Actavis Plc about a potential sale, sources have told Reuters in recent weeks.